Pfizer, Moderna vow appeals after split vaccine ruling
UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
9 July 2026 China-headquartered Angelalign failed to convince UPC appellate judges to overturn a ban that affects its ability to offer orthodontic planning software in Europe with certain functionality.
8 July 2026 UPC judges revoke a patent asserted against the companies over their Comirnaty COVID-19 vaccine, in a ruling that clarified the court’s key principles on exclusive licences, novelty and inventive step.
6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.